Sample Case #2
A. No, unless the sponsor has received a Written Request from FDA prior to submitting studies to the NDA.
Submitting data to satisfy the rule does not automatically result in an exclusivity extension. The type of information required for an exclusivity extension may be different in quantity and quality than that for complying with the rule.